22 October 2009 - Oxford Gene Technology (OGT) has been selected as the service provider for a study on copy number variation (CNV), published in the 'Nature' journal.
The article was entitled 'Origins and functional impact of copy number variation in the human genome'.
20 March 2009 - Oxford Gene Technology (OGT) has announced the acquisition of Sense Proteomic, a company engaged in the discovery of disease-specific biomarkers based on its protein array technology.
Sense Proteomic has identified biomarker panels for several diseases including prostate cancer and systemic lupus erythematosus, and has other biomarker discovery programmes in progress.
